Related Experiment Videos
Multidrug combination in cancer chemotherapy: MFU therapy
The Tohoku Journal of Experimental Medicine
|December 1, 1979
Summary
This study evaluated a three-drug chemotherapy regimen (Mitomycin-C, 5-fluorouracil, ACNU) for carcinoma patients. The MFU-II regimen showed promise with manageable side effects, particularly reduced hematological toxicity.
Area of Science:
- Oncology
- Medical Chemistry
- Pharmacology
Background:
- Carcinoma, particularly of the stomach, presents a significant therapeutic challenge.
- Combination chemotherapy is a cornerstone in managing advanced malignancies.
- Optimizing drug combinations and schedules is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and safety of a three-drug chemotherapy regimen comprising Mitomycin-C (MMC), 5-fluorouracil (5-FU), and ACNU in cancer patients.
- To compare different administration schedules (MFU-I, MFU-I-O, MFU-II) of this combination therapy.
- To assess the incidence and severity of side effects, particularly bone marrow suppression.
Main Methods:
- A total of 72 carcinoma patients, predominantly with stomach cancer, were treated with three different regimens: MFU-I, MFU-I-O (MFU-I plus OK-432), and MFU-II.
- Treatment efficacy was assessed using Karnofsky's criteria and criteria from the Grant-in-Aid for Cancer Research.
- Adverse events, focusing on hematological parameters like leukopenia and thrombocytopenia, were meticulously monitored.
Main Results:
- Objective responses (Karnofsky's criteria) were observed in 29% (MFU-I), 36% (MFU-I-O), and 30% (MFU-II) of patients.
- Partial responses (Grant-in-Aid criteria) were reported in 29% (MFU-I), 38% (MFU-I-O), and 30% (MFU-II) of patients.
- Bone marrow suppression (leukopenia, thrombocytopenia) was the most significant side effect, although MFU-II showed a trend towards less severe and quicker recovery, potentially aided by OK-432.
Conclusions:
- The three-drug combination of MMC, 5-FU, and ACNU demonstrates utility in treating malignant tumors, especially those of the digestive organs.
- The MFU-II treatment schedule appears to be a favorable option due to its relatively lower hematological side effects.
- Further investigation into optimizing this combination therapy, particularly the MFU-II schedule, is warranted to improve patient tolerance and efficacy.